Home > Understanding Breast Cancer > Treatment > Treatment References

  


Treatment References

 

  1. Altekruse SF, Kosary CL, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, 2010.
  2. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 59(1):56-66, 2009.
  3. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 305(6):569-75, 2011.
  4. Galimberti V, Botteri E, Chifu C, et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat. 2011 Apr 6. [Epub ahead of print].
  5. Chagpar AB, Studts JL, Scoggins CR, et al. for the University of Louisville Breast Sentinel Lymph Node Study. Factors associated with surgical options for breast carcinoma. Cancer. 106(7):1462-6, 2006.
  6. Smith GL, Xu Y, Shih YC, et al. Breast-conserving surgery in older patients with invasive breast cancer: current patterns of treatment across the United States. J Am Coll Surg. 209(4):425-433.e2, 2009.
  7. Lazovich D, Solomon CC, Thomas DB, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer. 86: 628-37, 1999.
  8. Buchholz TA and Hunk KK. Chapter 37: Breast-conserving therapy: conventional whole breast irradiation, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition. Lippincott Williams and Wilkins, 2010.
  9. National Cancer Institute. Radiation therapy and you: support for people with cancer. http://www.cancer.gov/cancertopics/radiation-therapy-and-you, 2007.
  10. Roychoudhuri R, Evans H. Robinson D, Møller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer. 91(5):868-72, 2004.
  11. Kirova YM, De Rycke Y, Gambotti L, Pierga J-Y, Asselain B, Fourquet A for the Institut Curie Breast Cancer Study Group. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 98(5):870-4, 2008.
  12. Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer. 115(18):4055-63, 2009.
  13. Shelley W, Brundage M, Hayter C, et al. A shorter fractionation schedule for postlumpectomy breast cancer patients. Int J Radiat Oncol Biol Phys. 47: 1219-28, 2000.
  14. Croog VJ, Wu AJ, McCormick B, Beal KP. Accelerated whole breast irradiation with intensity-modulated radiotherapy to the prone breast. Int J Radiat Oncol Biol Phys. 73(1):88-93, 2009.
  15. Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 362(6):513-20, 2010.
  16. Guenzi M, Vagge S, Azinwi NC, et al. A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects. Radiat Oncol. 5:111, 2010.
  17. Benitez PR, Keisch ME, Vicini F, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 194(4):456-62, 2007.
  18. Antonucci JV, Wallace M, Goldstein NS, et al. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up. Int J Radiat Oncol Biol Phys. 74(2):447-52, 2009.
  19. Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden M. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer. 116(20):4677-85, 2010.
  20. Polgár C, Major T, Fodor J, et al. Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol. 94(3):274-9, 2010.
  21. Richardson LC, Wang W, Hartzema AG, Wagner S. The role of health-related quality of life in early discontinuation of chemotherapy for breast cancer. Breast J. 13(6):581-7, 2007.
  22. National Cancer Institute. Chemotherapy and you: support for people with cancer. http://www.cancer.gov/cancertopics/coping/chemotherapy-and-you/page7#SE7, 2007.
  23. Partridge AH, Winer EP. Long-term complications of adjuvant chemotherapy for early stage breast cancer. Breast Dis. 21:55-64, 2004.
  24. Saquib N, Flatt SW, Natarajan L, et al. Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women's healthy eating and living (WHEL) study. Breast Cancer Res Treat. 105(2):177-86, 2007.
  25. Lyman GH, Kuderer NM. Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a meta analysis. Clin Breast Cancer. 7(5):372-9, 2006.
  26. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med, 2004.
  27. Genomic Health, Inc. Oncotype Dx: Breast cancer assay. http://www.oncotypedx.com/, 2011.
  28. Acharya CR, Hsu DS, Anders CK, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 299(13):1574-87, 2008.
  29. Pedraza V, Gomez-Capilla JA, Escaramis G, et al. Gene expression signatures in breast cancer distinguish phenotype characteristics, histologic subtypes, and tumor invasiveness. Cancer. 116(2):486-96, 2010.
  30. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 101(1):113-21, 2007.
  31. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 28(8):1287-93, 2010.
  32. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 302(13):1429-36, 2009.
  33. Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 115(5):952-61, 2009.
  34. Gralow JR, Biermann JS, Farooki A, et al. NCCN Task Force report: Bone health in cancer care. J Natl Compr Canc Netw. 7 Suppl 3:S1-S32, 2009.
  35. Hillner BE, Ingle JN, Chlebowski RT, et al. for the American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 21(21):4042-57, 2003.
  36. Gnant M, Mlineritsch B, Schippinger W, et al. for the ABCSG-12 Trial Investigators, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 360(7):679-91, 2009.
  37. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 19(3):420-32, 2008.
  38. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 361(2):123-34, 2009.
  39. Muss HB, Berry DA, Cirrincione CT, et al. for the CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 360(20):2055-65, 2009.
  40. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. for the FinXX Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol. 10(12):1145-51, 2009.
  41. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 342: 1069-76, 2000.
  42. Farquhar C, Marjoribanks J, Basser R et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer (Review). The Cochrane Database Syst Rev. 3:CD003142.pub2, 2005.
  43. Kröger N, Frick M, Gluz O, et al. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol. 24(24):3919-26, 2006.
  44. Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol. 26(1):37-43, 2008.
  45. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 365(9472):1687-717, 2005.
  46. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 28(3):509-18, 2010.
  47. Murphy B and Muss HB. Hormonal therapy of breast cancer: state of the art. Oncology (Huntingt). 11: 7-13, 1997.
  48. McCowan C, Shearer J, Donnan PT, et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 99(11):1763-8, 2008.
  49. National Cancer Institute. Tamoxifen. http://www.cancer.gov/cancertopics/factsheet/Therapy/tamoxifen, 2008.
  50. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 340:c693, 2010.
  51. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 97(22):1652-62, 2005.
  52. Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 18 Suppl 8:viii26-35, 2007.
  53. Jakesz R, Jonat W, Gnant M, et al. on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) and the German Adjuvant Breast Cancer Group (GABG). Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 366(9484):455-62, 2005.
  54. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al. for the BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 361(8):766-76, 2009.
  55. Coombes RC, Kilburn LS, Snowdon CF, et al. for the Intergroup Exemestane Study (IES). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 369(9561):559-70, 2007.
  56. Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 25(19):2664-70, 2007.
  57. Forbes JF, Cuzick J, Budzar A, Howell A, Tobias JS, Baum M for the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9(1):45-53, 2008.
  58. Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 26(12):1948-55, 2008.
  59. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 26(12):1956-64, 2008.
  60. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 25(36):5715-22, 2007.
  61. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 26(7):1051-7, 2008.
  62. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 19(8):1407-16, 2008.
  63. U.S. Food and Drug Administration. Bisphosphonates information. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm101551.htm, 2010.
  64. Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. (4):CD004562, 2008.
  65. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study. JAMA. 295(21):24922502, 2006.
  66. National Comprehensive Cancer Network. NCCN Clinical practices guidelines in oncology: Breast cancer. V.2.2011. http://www.nccn.org, 2011.
  67. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353(16):1673-84, 2005.
  68. Smith I, Procter M, Gelber RD, et al. for the Herceptin Adjuvant (HERA) study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369(9555):29-36, 2007.
  69. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 13(6):620-30, 2008.
  70. Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol. 28(21):3422-8, 2010.
  71. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 18(12):1927-34, 2007.
  72. Mieog JSD, van der Hage JA, van de Velde CJH. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 94(10):1189-1200, 2007.
  73. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011 May 9 [Epub ahead of print].
  74. Classe JM, Bordes V, Campion L, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 27(5):726-32, 2009.
  75. Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 16(5):551-63, 2009.
  76. Morrow M and Harris JR. Chapter 26: Ductal carcinoma in situ and microinvasive carcinoma, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition. Lippincott Williams and Wilkins, 2010.
  77. Joslyn SA. Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival. Breast J. 12(1):20-7, 2006.
  78. Houghton J, George WD, Cuzick J, et al. for the UK Coordinating Committee on Cancer Research (UKCCCR) Ductal Carcinoma in situ (DCIS) Working Party on behalf of DCIS Trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 362(9378):95-102, 2003.
  79. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 27(32):5319-24, 2009.
  80. Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev. (3):CD000563, 2009.
  81. Correa C, McGale P, Taylor C, Wang Y, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010(41):162-77, 2010.
  82. Kane RL, Virnig BA, Shamliyan T, Wang SY, Tuttle TM, Wilt TJ. The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010(41):130-3, 2010.
  83. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 12(1):21-9, 2011.
  84. Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 103(6):478-88, 2011.
  85. Boyages J, Delaney G, Taylor R. Predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Cancer. 85(3):616-28, 1999.
  86. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 8(9):1377-85, 2008.
  87. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). Chapter 13: Cancer of the female breast, In SEER Survival Monograph: Cancer survival among adults: U.S. SEER Program, 1988-2001, patient and tumor characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD. http://seer.cancer.gov/publications/survival/surv_breast.pdf, 2007.
  88. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 23(16):3676-85, 2005.
  89. Carlson RW. Chapter 70: Surveillance of patients following primary therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition. Lippincott Williams and Wilkins, 2010.
  90. Clarke M, Collins R, Darby S, et al. for the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 366(9503):2087-106, 2005.
  91. Golshan M. Chapter 36: Mastectomy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition. Lippincott Williams and Wilkins, 2010.
  92. Merajver SD, Iniesta MD, Sabel MS. Chapter 62: Inflammatory Breast Cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition, Lippincott Williams & Wilkins, 2010.
  93. Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 55(5):1200-8, 2003.
  94. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 27(18):2938-45, 2009.
  95. Yang R, Cheung MC, Hurley J, et al. A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Res Treat. 117(3):631-41, 2009.
  96. American Cancer Society. Breast Cancer Facts & Figures 2009-2010, 2009.
  97. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R for the Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 19(2):343-53, 2001.
  98. Howell SJ and Howell A. Chapter 73: Treatment of metastatic breast cancer-endocrine therapy, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition. Lippincott Williams and Wilkins, 2010.
  99. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344: 783-92, 2001.
  100. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 22(6):1063-70, 2004.
  101. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 24(18):2786-92, 2006.
  102. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 26(10):1642-9, 2008.
  103. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 28(7):1124-30, 2010.
  104. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355(26):2733-43, 2006.
  105. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 27(33):5538-46, 2009.
  106. Toi M, Iwata H, Fujiwara Y, et al. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer. 101(10):1676-82, 2009.
  107. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases - the UK experience. Br J Cancer. 102(6):995-1002, 2010.
  108. Metro G, Foglietta J, Russillo M, et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol. 22(3):625-30, 2011.
  109. U.S. Food and Drug Administration. Labeling information for lapatinib (Tykerb). http://www.fda.gov/, 2010.
  110. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 357(26):2666-76, 2007.
  111. U.S. Food and Drug Administration. Avastin Information. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm193900.htm, 2011.
  112. U.S. Food and Drug Administration. FDA Commissioner announces Avastin decision. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280536.htm, 2011.
  113. National Cancer Institute. Eating hints for cancer patients: before, during, and after treatment. http://www.cancer.gov/cancertopics/eatinghints/page4, 2009.
  114. Jones M, Schenkel B, Just J, Fallowfield L. Epoetin alfa improves quality of life in patients with cancer: results of meta analysis. Cancer. 101(8):1720-32, 2004.
  115. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 26(4):592-8, 2008.
  116. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 26(1):132-49, 2008.
  117. Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst. 101(23):1633-41, 2009.
  118. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 8(2):R13, 2006.
  119. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 96(12):1796-801, 2007.
  120. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 364(3):205-14, 2011.
  121. Patel SA and Topham NS. Chapter 39: Breast reconstruction, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition. Lippincott Williams and Wilkins, 2010.
  122. Olsen MA, Lefta M, Dietz JR, et al. Risk factors for surgical site infection after major breast operation. J Am Coll Surg. 207(3):326-35, 2008.
  123. Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med. 342(11):781-90, 2000.
  124. Center for Devices and Radiological Health, U.S. Food and Drug Administration. Anaplastic large cell lymphoma (ALCL) in women with breast implants: Preliminary FDA findings and analyses. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm, 2011.
  125. Kim B, Roth C, Chung KC, et al. Anaplastic large cell lymphoma and breast implants: A systematic review. Plast Reconstr Surg. 2011 Mar 25. [Epub ahead of print].
  126. Eaves FF, Haeck P, Rohrich RJ. Breast implants and anaplastic large cell lymphoma (ALCL): Using science to guide our patients and plastic surgeons worldwide. Plast Reconstr Surg. 2011 Mar 25. [Epub ahead of print].
  127. Breuing KH, Warren SM. Immediate bilateral breast reconstruction with implants and inferolateral AlloDerm slings. Ann Plast Surg. 55(3):232-9, 2005.
  128. Salzberg CA, Ashikari AY, Koch RM, Chabner-Thompson E. An 8-year experience of direct-to-implant immediate breast reconstruction using human acellular dermal matrix (AlloDerm). Plast Reconstr Surg. 127(2):514-24, 2011.
  129. United States Food and Drug Administration (FDA). Breast implants. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/default.htm, 2009.
  130. American Society for Aesthetic Plastic Surgery and American Society of Plastic Surgeons. Breast implants. http://www.surgery.org/consumers/procedures/breast/breast-implants, 2009.
  131. The University of Texas MD Anderson Cancer Center. Reshaping you: Options for breast reconstruction. http://www2.mdanderson.org/app/pe/index.cfm?pageName=opendoc&docid=3116, 2009.
  132. Man LX, Selber JC, Serletti JM. Abdominal wall following free TRAM or DIEP flap reconstruction: a meta-analysis and critical review. Plast Reconstr Surg. 124(3):752-64, 2009.
  133. Selber JC, Samra F, Bristol M, et al. A head-to-head comparison between the muscle-sparing free TRAM and the SIEA Flaps: is the rate of flap loss worth the gain in abdominal wall function? Plast Reconstr Surg. 122(2):348-55, 2008.
  134. Granzow JW, Levine JL, Chiu ES, Allen RJ. Breast reconstruction using perforator flaps. J Surg Oncol. 94(6):441-54, 2006.
  135. Cunnick GH, Mokbel K. Skin-sparing mastectomy. Am J Surg. 188(1):78-84, 2004.
  136. Greenway RM, Schlossberg L, Dooley WC. Fifteen-year series of skin-sparing mastectomy for stage 0 to 2 breast cancer. Am J Surg. 190(6):918-22, 2005.
  137. Gerber B, Krause A, Dieterich M, Kundt G, Reimer T. The oncological safety of skin sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction: an extended follow-up study. Ann Surg. 249(3):461-8, 2009.
  138. Garwood ER, Moore D, Ewing C, et al. Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann Surg. 249(1):26-32, 2009.
  139. Lanitis S, Tekkis PP, Sgourakis G, Dimopoulos N, Al Mufti R, Hadjiminas DJ. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg. 251(4):632-9, 2010.
  140. Benediktsson KP, Perbeck L. Survival in breast cancer after nipple-sparing subcutaneous mastectomy and immediate reconstruction with implants: a prospective trial with 13 years median follow-up in 216 patients. Eur J Surg Oncol. 34(2):143-8, 2008.
  141. Crowe JP, Patrick RJ, Yetman RJ, Djohan R. Nipple-sparing mastectomy update: one hundred forty-nine procedures and clinical outcomes. Arch Surg. 143(11):1106-10, 2008.
  142. Petit JY, Veronesi U, Orecchia R, et al. Nipple sparing mastectomy with nipple areola intraoperative radiotherapy: one thousand and one cases of a five years experience at the European institute of oncology of Milan (EIO). Breast Cancer Res Treat. 117(2):333-8, 2009.
  143. American Cancer Society. Breast reconstruction after mastectomy. http://www.cancer.org/docroot/CRI/content/CRI_2_6X_Breast_Reconstruction_After_Mastectomy_5.asp, 2009.
  144. U.S. Department of Labor. Fact sheet: Women’s Health and Cancer Rights Act. http://www.dol.gov/ebsa/newsroom/fswhcra.html, 2011.
  145. National Cancer Institute. Breast cancer treatment and pregnancy. http://www.dol.gov/ebsa/newsroom/fswhcra.html, 2010.
  146. Litton JK and Theriault RL. Chapter 68: Breast cancer during pregnancy and subsequent pregnancy in breast cancer survivors, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 4th edition. Lippincott Williams and Wilkins, 2010.
  147. Mir O, Berveiller P, Ropert S, Goffinet F, Pons G, Treluyer JM, Goldwasser F. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol. 19(4):607-13, 2008.
  148. American Cancer Society. Cancer Facts & Figures 2010, 2010.
  149. National Cancer Institute. Male breast cancer treatment. http://www.cancer.gov/cancertopics/pdq/treatment/malebreast/Patient, 2010.
  150. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 28(2):232-9, 2010.
  151. Altekruse SF, Kosary CL, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2007: Fast Stats. Bethesdsa, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2007/index.html, 2010.
  152. American Society of Clinical Oncology. Breast cancer – male. http://www.cancer.net/, 2010.
  153. Mayo Clinic Staff. Male breast cancer. Mayo Clinic. http://www.mayoclinic.com/health/male-breast-cancer/DS00661, 2010.
  154. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 353(5):487-97, 2005.
  155. American Cancer Society. Making treatment decisions: Clinical trials-what you need to know. http://our.cancer.org/docroot/ETO/content/ETO_6_3_Clinical_Trials_-_Patient_Participation.asp, 2009.
  156. National Cancer Institute. Participating in a Trial: Questions to ask your doctor. http://www.cancer.gov/clinicaltrials/learning/questions-to-ask-about-participating, 2008.
  157. Soliman H. Developing an effective breast cancer vaccine. Cancer Control. 17(3):183-90, 2010.
  158. Cherny NI. Chapter 84: Brachial plexopathy in patients with breast cancer, in Harris JR LM, Morrow M, Osborne CK. Diseases of the Breast, Lippincott Williams and Wilkins, 2010.
  159. Whelan TJ, Levine M, Julian J, Kirkbride P, Skingley P for the Ontario Clinical Oncology Group. The effects of radiation therapy on quality of life of women with breast carcinoma: results of a randomized trial. Ontario Clinical Oncology Group. Cancer. 88(10):2260-6, 2000.
  160. World Health Organization (WHO). Cancer Pain Relief, second edition. Geneva: WHO, 1996.
  161. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Adult cancer pain V.1.2011. http://www.nccn.org/, 2011.
  162. American Cancer Society. Pain control: A guide for people with cancer and their families. http://www.cancer.org/Treatment/TreatmentsandSideEffects/PhysicalSideEffects/Pain/PainDiary/index, 2010.
  163. National Cancer Institute. Pain control: Support for people with cancer. http://www.cancer.gov/cancertopics/paincontrol/allpages, 2008.  
  164. American Cancer Society. Breast cancer survival rates by stage. http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-survival-by-stage, 2011.
  165. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 28(35):5132-9, 2010.
  166. Slamon D, Eiermann W, Robert N, et al. for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 365(14):1273-83, 2011.
  167. Coleman RE, Marshall H, Cameron D, et al. for the AZURE Investigators. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011 Sept 25. [Epub ahead of print].  
  168. American Cancer Society. Cancer Facts & Figures 2012, 2012.

Updated 01/19/12

010673.gif  Treatment Home      

  

Related Links

Visited by Others

Komen Videos